These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 17656039)

  • 1. CD34+ fibrocytes are preserved in most invasive lobular carcinomas of the breast.
    Ebrahimsade S; Westhoff CC; Barth PJ
    Pathol Res Pract; 2007; 203(9):695-8. PubMed ID: 17656039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD34+ fibrocytes in invasive ductal carcinoma, ductal carcinoma in situ, and benign breast lesions.
    Barth PJ; Ebrahimsade S; Ramaswamy A; Moll R
    Virchows Arch; 2002 Mar; 440(3):298-303. PubMed ID: 11889601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic significance of the immunoexpression of CD34 and smooth muscle cell actin in benign and malignant tumors of the breast.
    Cîmpean AM; Raica M; Nariţa D
    Rom J Morphol Embryol; 2005; 46(2):123-9. PubMed ID: 16286998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic relevance of the loss of stromal CD34 positive fibroblasts in invasive lobular carcinoma of the breast.
    Westhoff CC; Jank P; Jacke CO; Albert US; Ebrahimsade S; Barth PJ; Moll R
    Virchows Arch; 2020 Nov; 477(5):717-724. PubMed ID: 32435886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of proteoglycan versican in in situ breast lesions: relations between stromal changes, histotype, and invasion.
    Canavese G; Candelaresi G; Castellano I; Mano MP
    Pathol Res Pract; 2011 Feb; 207(2):97-103. PubMed ID: 21185131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD34+ fibrocytes, alpha-smooth muscle antigen-positive myofibroblasts, and CD117 expression in the stroma of invasive squamous cell carcinomas of the oral cavity, pharynx, and larynx.
    Barth PJ; Schenck zu Schweinsberg T; Ramaswamy A; Moll R
    Virchows Arch; 2004 Mar; 444(3):231-4. PubMed ID: 14758552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma?
    Sullivan PS; Apple SK
    Breast J; 2009; 15(2):146-54. PubMed ID: 19292800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD34+ fibrocytes in tubular carcinomas and radial scars of the breast.
    Ramaswamy A; Moll R; Barth PJ
    Virchows Arch; 2003 Oct; 443(4):536-40. PubMed ID: 12898244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD34+ fibrocytes in chronic cystitis and noninvasive and invasive urothelial carcinomas of the urinary bladder.
    Nimphius W; Moll R; Olbert P; Ramaswamy A; Barth PJ
    Virchows Arch; 2007 Feb; 450(2):179-85. PubMed ID: 17149610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Breast lesions with moderate and high risk of invasive breast cancer--incidence and some particularities].
    Ivanov I; Baĭchev G; Betova T
    Akush Ginekol (Sofiia); 2008; 47(5):17-21. PubMed ID: 19230257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological significance of stromal myofibroblasts in invasive ductal carcinoma of the breast.
    Yazhou C; Wenlv S; Weidong Z; Licun W
    Tumour Biol; 2004; 25(5-6):290-5. PubMed ID: 15627894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consistent lack of CD34-positive stromal cells in the stroma of malignant breast lesions.
    Kuroda N; Jin YL; Hamauzu T; Toi M; Miyazaki E; Hiroi M; Moriki T; Enzan H
    Histol Histopathol; 2005 Jul; 20(3):707-12. PubMed ID: 15944918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variable stromal periductular expression of CD34 and smooth muscle actin (SMA) in intraductal carcinoma of the breast.
    Catteau X; Simon P; Vanhaeverbeek M; Noël JC
    PLoS One; 2013; 8(3):e57773. PubMed ID: 23469238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In situ and invasive lobular neoplasia of the breast.
    Hanby AM; Hughes TA
    Histopathology; 2008 Jan; 52(1):58-66. PubMed ID: 18171417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invasive lobular carcinoma of the breast: role of endothelial lymphatic marker D2-40.
    Laser J; Cangiarella J; Singh B; Melamed J; Chiriboga L; Yee H; Darvishian F
    Ann Clin Lab Sci; 2008; 38(2):99-104. PubMed ID: 18469353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of prognostic significance of "classic" lobular breast carcinoma: a matched, single institution series.
    Viale G; Rotmensz N; Maisonneuve P; Orvieto E; Maiorano E; Galimberti V; Luini A; Colleoni M; Goldhirsch A; Coates AS
    Breast Cancer Res Treat; 2009 Sep; 117(1):211-4. PubMed ID: 18629634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Lobular carcinoma in situ (LCIS): risk factor and precursor of invasive lobular breast cancer].
    Aulmann S; Penzel R; Schirmacher P; Sinn HP
    Verh Dtsch Ges Pathol; 2007; 91():208-13. PubMed ID: 18314616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The analysis of CD34 antigen immunoreactivity level in invasive ductal breast cancer with respect to the presence of lymph node metastases.
    Popiela TJ; Sikora J; Klimek M; Basta P; Niemiec T; Dobrogowski J; Kotlarz A; Rudnicka-Sosin L; Dutsch-Wicherek M
    Neuro Endocrinol Lett; 2008 Aug; 29(4):443-6. PubMed ID: 18766141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
    Fadare O; Wang SA; Hileeto D
    Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokeratins 7 and 14 in special types of invasive breast carcinomas.
    Toth T
    Med Pregl; 1999; 52(6-8):227-32. PubMed ID: 10518377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.